InsidersTradesSigma
Track the CytoDyn Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, CytoDyn Inc. has published 47 public disclosures. Market capitalisation: €287.6m. The latest transaction was filed on 14 February 2023 (Attribution). Among the most active insiders: Kelly Scott A.. Every trade is accessible without an account.
47
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 February 2023
Declarations47 total
434,782 sharesCommon StockSEC:0001104659-23-022094:0
16,927 shares0Common StockSEC:0001104659-22-123365:0
12,008 shares0Common StockSEC:0001104659-22-123366:0
15,234 shares0Common StockSEC:0001104659-22-119979:0
10,807 shares0Common StockSEC:0001104659-22-119981:0
13,671 shares0Common StockSEC:0001104659-22-119978:0
16,084 shares0Common StockSEC:0001104659-22-114098:0
12,714 shares0Common StockSEC:0001104659-22-114100:0
17,922 shares0Common StockSEC:0001104659-22-114101:0
9,824 shares0Common StockSEC:0001104659-22-109690:0
13,849 shares0Common StockSEC:0001104659-22-109687:0
12,428 shares0Common StockSEC:0001104659-22-109693:0
18,793 shares0Common StockSEC:0001104659-22-105980:0
10,292 shares0Common StockSEC:0001104659-22-105981:0
13,020 shares0Common StockSEC:0001104659-22-105983:0
646,552 shares0Common StockSEC:0001104659-22-102416:0
8,965 shares0Common StockSEC:0001104659-22-101254:0
9,457 shares0Common StockSEC:0001104659-22-101258:0
7,086 shares0Common StockSEC:0001104659-22-101256:0
10,516 shares0Common StockSEC:0001104659-22-097602:0
11,094 shares0Common StockSEC:0001104659-22-097603:0
8,313 shares0Common StockSEC:0001104659-22-097604:0
6,588 shares0Common StockSEC:0001104659-22-092175:0
5,208 shares0Common StockSEC:0001104659-22-092173:0
6,950 shares0Common StockSEC:0001104659-22-092174:0
25 of 47 declarations
关于 CytoDyn Inc.
从地理上看，CytoDyn 主要在美国运营，总部设在华盛顿州温哥华。该公司的开发工作集中在美国的临床和监管途径，并与美国研究机构进行学术合作。近期里程碑对市场认知很重要：2026年公布了新的肿瘤学数据，2026年4月30日举行了投资者网络研讨会，公司公开讨论了正在进行的2期结直肠癌工作和计划中的2期 mTNBC 活动。对于法国、比利时和瑞士的投资者而言，CytoDyn 应被视为一家投机性临床阶段生物技术公司，拥有一项主导的科学论点，如果其 CCR5/leronlimab 项目成功，则具有显著的上涨选择权，如果临床或监管结果令人失望，则存在巨大的执行风险。
